Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04725097 · ClinicalTrials.gov registry record

A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection

A clinical trial, sponsored by Mayo Clinic.

Terminated
Registry status
2,821
Enrollment target

NCT04725097: Clinical Trial study, sponsored by Mayo Clinic.

NCT04725097 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 2,821 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04725097 was terminated before completion, sponsored by Mayo Clinic.

TERMINATED
Registry status
2,821 participants
Enrollment target

Study Summary

The purpose of this study is to assess the ability of an artificial intelligence smartphone-enabled point of care ECG to detect COVID-19.

Primary Outcome

Determine the safety and feasibility of the POC AI-ECG's ability to detect active SARS-Cov-2 infection in humans.

Trial Details

FieldValue
Enrollment Target 2,821 participants
Start Date 2020-12-10
Est. Completion 2021-06-03
Mayo Clinic

2,844 total trials

Why NCT04725097 stopped before completion

NCT04725097 is an observational study that tracks outcomes without assigning an intervention. Its 2,821 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT04725097 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04725097 about?

NCT04725097 is a clinical study titled "A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection". The purpose of this study is to assess the ability of an artificial intelligence smartphone-enabled point of care ECG to detect COVID-19.

What is the current status of trial NCT04725097?

This trial is currently terminated. The enrollment target is 2,821 participants. The study started on 2020-12-10. Estimated completion is 2021-06-03.

Who is sponsoring clinical trial NCT04725097?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02273297 · 2,821 participants

    Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth

  • NCT05932602 · 2,812 participants

    AVEIR DR Coverage With Evidence Development (CED) Study

  • NCT06150781 · 2,842 participants

    Aimovig Pregnancy Exposure Registry

  • NCT05443737 · 2,800 participants · Phase 3

    Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04725097, the US trial registry maintained by the National Library of Medicine. NCT04725097 (large enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.